论文部分内容阅读
2型糖尿病合并血脂代谢异常患者63例,在入组及治疗6周后测定空腹血清总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、肝肾功、血尿酸及纤维蛋白原,记录临床症状及不良反应,对治疗前后进行比较。结果瑞舒伐他汀治疗后TG、TC和LDL-C水平明显下降(P<0.05),与治疗前相比有统计学意义,HDL-C在治疗前后无明显变化,差异无统计学意义(P>0.05)。所有患者未发生严重不良事件,肝肾功、血尿酸及纤维蛋白原水平未出现异常,治疗前后无明显改变。结论瑞舒伐他汀在2型糖尿病合并血脂代谢紊乱人群中降脂治疗是有效的、安全的。
Sixty-three patients with type 2 diabetes mellitus and dyslipidemia were involved in the study. Fasting serum total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein Cholesterol (LDL-C), liver and kidney function, serum uric acid and fibrinogen, clinical symptoms and adverse reactions were recorded before and after treatment were compared. Results After treatment with rosuvastatin, the levels of TG, TC and LDL-C were significantly decreased (P <0.05), compared with before treatment, there was no significant difference in HDL-C before and after treatment (P > 0.05). All patients did not have serious adverse events, liver and kidney function, serum uric acid and fibrinogen levels did not appear abnormal, no significant change before and after treatment. Conclusion Rosuvastatin is effective and safe in the treatment of type 2 diabetes with dyslipidemia.